India, Feb. 18 -- Northstrive Biosciences, a subsidiary of PMGC Holdings Inc. (ELAB), on Tuesday announced the submission of a pre-investigational New Drug or pre-IND meeting request to the FDA for EL-22.
EL-22, a novel myostatin-targeting asset, aims to preserve muscle mass while on weight loss treatments. The current GLP-1 agonist therapies approved for chronic weight management are frequently linked to considerable muscle loss.
In a preclinical model of Duchenne muscular dystrophy, EL-22 showed significant physiological and functional improvements. In a phase I trial, conducted in South Korea, in healthy volunteers, EL-22 was found to be generally well-tolerated and safe.
The upcoming pre-IND meeting, expected in the second quarter of...